Guardant Health financials
$177.73+0.23%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $335.0M | $301.7M | $281.3M | $265.2M | $232.1M | $203.5M | $201.8M | $191.5M | $177.2M | $168.5M | $155.1M | $143.0M |
| Gross profit | $219.0M | $196.7M | $181.8M | $171.6M | $150.9M | $128.7M | $124.2M | $117.0M | $104.8M | $103.2M | $92.5M | $85.4M |
| Gross margin | 65.4% | 65.2% | 64.6% | 64.7% | 65.0% | 63.3% | 61.6% | 61.1% | 59.1% | 61.2% | 59.7% | 59.7% |
| Operating income | -$129.1M | -$121.3M | -$120.8M | -$99.0M | -$106.4M | -$111.0M | -$126.0M | -$117.3M | -$100.6M | -$99.7M | -$197.5M | -$113.5M |
| Net income | -$120.1M | -$112.1M | -$128.5M | -$92.7M | -$99.9M | -$95.2M | -$111.0M | -$107.8M | -$102.6M | -$115.0M | -$187.0M | -$86.1M |
| Net margin | −35.9% | −37.2% | −45.7% | −35.0% | −43.0% | −46.8% | −55.0% | −56.3% | −57.9% | −68.2% | −120.6% | −60.2% |
| Diluted EPS | $-0.90 | $-0.85 | $-1.00 | $-0.74 | $-0.80 | $-0.77 | $-0.90 | $-0.88 | $-0.84 | $-0.94 | $-1.58 | $-0.73 |
| EBITDA | -$119.6M | -$111.9M | -$110.8M | -$89.6M | -$96.4M | -$100.8M | -$115.5M | -$106.7M | -$90.0M | -$89.0M | -$197.5M | -$102.5M |
| Operating cash flow | -$57.8M | -$65.6M | -$26.4M | -$35.4M | -$60.3M | -$62.7M | -$64.5M | -$51.1M | -$94.0M | -$30.3M | -$78.8M | -$77.8M |
| Free cash flow | -$69.5M | -$71.2M | -$54.2M | -$45.8M | -$65.9M | -$67.1M | -$83.4M | -$55.3M | -$99.1M | -$37.2M | -$82.9M | -$80.2M |
| Diluted shares | 132.9M | 131.3M | 128.7M | 124.8M | 124.1M | 123.9M | 123.8M | 123.1M | 122.4M | 121.7M | 118.7M | 117.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.05B | $989.3M | $378.2M | $580.0M | $629.1M | $698.6M |
| Short-term investments | $0.00 | $113.5M | $823.4M | $0.00 | $0.00 | $0.00 |
| Total debt | $1.50B | $1.50B | $1.50B | $1.11B | $1.12B | $1.12B |
| Total assets | $1.91B | $1.92B | $2.01B | $1.28B | $1.33B | $1.34B |
| Total liabilities | $2.14B | $2.10B | $2.11B | $1.63B | $1.64B | $1.60B |
| Shareholders' equity | -$222.9M | -$181.1M | -$99.3M | -$354.5M | -$305.5M | -$250.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology